SIGACHI · NSE
Sigachi Industries Limited
₹29.6
+0.92% (+₹0.27)
Prev. close
₹29.33
Volume
1,63,77,369
Delivery %
34.8%
As of
18 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Sigachi Industries Limited
Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company provides cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab brand names to pharmaceutical, nutraceutical, cosmetic, and chemical industries. It also provides croscarmellose sodium, pharmaceutical coatings, nutritional premix and food solutions, and allied trade business, as well as operations and maintenance services. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Mr. Amit Raj Sinha
Headquarters
Hyderabad
Employees
1,400
Website
sigachi.comExchange
View on NSE ↗Key stats
Market cap
₹1,132.16 Cr
P/E ratio (TTM)
44.2
Dividend yield
0.34%
EPS (TTM)
₹0.67
Beta (1Y · daily vs NIFTY 50)
1.31
Beta (5Y · monthly vs NIFTY 50)
1.34
Shares float
18.46 Cr
EPS · quarter ended Jun 2026
₹0.18
Financial Performance
01 · Financials
FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹250.29 Cr | ₹302.05 Cr | ₹398.96 Cr | ₹488.24 Cr | ₹477.83 Cr | |
| EBITDA | — | ₹55.67 Cr | ₹65.40 Cr | ₹88.34 Cr | ₹120.51 Cr | ₹-57.33 Cr |
| — | ₹40.04 Cr | ₹43.54 Cr | ₹57.18 Cr | ₹69.56 Cr | ₹-81.76 Cr | |
| Diluted EPS | — | ₹1.54 | ₹1.42 | ₹1.54 | ₹2.06 | ₹-2.14 |
Revenue, Total expenses (as filed), Employee benefit expense, Depreciation & amortisation, Other expenses, EBITDA, Net income, Pretax income, Tax provision, Interest expense, Other income, Diluted EPS have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹133.41 Cr | ₹286.80 Cr | ₹373.75 Cr | ₹694.16 Cr | ₹846.21 Cr | ₹841.17 Cr | |
| ₹20.20 Cr | ₹34.33 Cr | ₹68.48 Cr | ₹151.07 Cr | ₹142.31 Cr | ₹162.26 Cr | |
| Stockholders' equity | ₹94.20 Cr | ₹227.78 Cr | ₹268.36 Cr | ₹429.64 Cr | ₹600.85 Cr | ₹521.72 Cr |
Fixed assets, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | ₹5.85 Cr | ₹29.02 Cr | ₹12.89 Cr | ₹26.93 Cr | ₹-42.80 Cr | |
| Investing cash flow | — | ₹-62.86 Cr | ₹-91.85 Cr | ₹-160.74 Cr | ₹-93.07 Cr | ₹-5.45 Cr |
| — | ₹108.37 Cr | ₹26.21 Cr | ₹172.10 Cr | ₹81.10 Cr | ₹2.24 Cr | |
| Capital expenditure | — | ₹-24.33 Cr | ₹-100.72 Cr | ₹-85.19 Cr | ₹-43.33 Cr | ₹-44.95 Cr |
| End cash position | — | ₹69.38 Cr | ₹32.76 Cr | ₹57.06 Cr | ₹72.02 Cr | ₹26.01 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Nov 21 | Dec 21–Sep 22(4Q) | Dec 22–Sep 23(4Q) | Oct 23–Dec 23(2Q) | Mar 24–Jun 24(3Q) | Aug 24–Dec 24(3Q) | Feb 25–Jun 25(3Q) | Sep 25 | Dec 25 | Mar 26–Jun 26(2Q) |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 48.46% | 48.48% | 48.49% | 46.08% | 45.43% | 44.71% | 44.14% | 40.48% | 39.70% | 36.69% |
| Public | 51.54% | 51.52% | 51.51% | 53.92% | 54.57% | 55.29% | 55.86% | 59.52% | 60.30% | 63.31% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Sigachi Industries Limited | ₹1,191.82 Cr | ₹29.33 | 47.2 | 2.28 | -15.7% | 0.31 | -2.1% | -33.9% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Concall transcripts
Show all 11
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.
SIGACHI INDUSTRIES Share Price Today Down 7%
Sigachi Industries' share price fell 7% to Rs 29.0, while the BSE Healthcare index rose 1.1%. Over the past year, the company's stock has declined 33.7%, contrasting with the BSE Healthcare index's 13.9% gain. The company reported a 108.1% year-over-year net profit increase for the quarter ended June 2026.
Projecting 8–10% CAGR on rising demand for performance-focused O&M: S. Chidambaranathan, Executive Vice Chairman, Sigachi Industries
Sigachi Industries expects its Operations & Maintenance (O&M) business to grow at an 8-10% CAGR, driven by increasing demand for reliability-focused and technology-enabled solutions. The company is seeing strong demand across specialty chemicals, pharmaceutical ingredients, and advanced materials. Sigachi aims to differentiate itself through a consulting-led approach that focuses on improving plant reliability and operational performance.